Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06943534 · ClinicalTrials.gov registry record · Phase 2
Omalizumab Weight-Based Dosing Efficacy Trial
A Phase 2 study of Food Allergy and Allergies, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06943534 is a Phase 2 study of Food Allergy and Allergies that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 962-participant average among 17 other Food Allergy trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06943534, a Phase 2 study of Food Allergy and Allergies, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.
Conditions Studied
Interventions
- DRUG 5mg/kg omalizumab injection
- DRUG 15mg/kg omalizumab injection
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-07-03 |
| Est. Completion | 2028-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06943534
The ClinicalTrials.gov registry entry for NCT06943534 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 962-participant average among 17 other Food Allergy trials with a reported enrollment target (97% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Food Allergy appearing as the primary indexed condition, and to 2 interventions - of which 5mg/kg omalizumab injection is the first listed.
NCT06943534 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT06943534 about?
NCT06943534 is a clinical study titled "Omalizumab Weight-Based Dosing Efficacy Trial". This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.
What is the current status of trial NCT06943534?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-07-03. Estimated completion is 2028-04-01.
What conditions does trial NCT06943534 study?
This clinical trial studies the following conditions: Food Allergy, Allergies.
What interventions are being tested in trial NCT06943534?
The interventions under investigation include: 5mg/kg omalizumab injection (DRUG), 15mg/kg omalizumab injection (DRUG).
Who is sponsoring clinical trial NCT06943534?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06943534 being conducted?
This trial has 3 study locations across Massachusetts, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
COMPLETED · Phase 2
-
Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
COMPLETED · Phase 2
-
Multi Immunotherapy to Test Tolerance and Xolair
COMPLETED · Phase 2
-
Preventing Anaphylaxis With Acalabrutinib
COMPLETED · Phase 2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.